StockIQpro
NYSE:MANE

Veradermics, Inc

Track all markets on TradingView
Track all markets on TradingView

Veradermics, Inc reported net income of −$70.0M in fiscal 2025. Free cash flow was −$71.6M, and the diluted share count rose 1.1%.Summary generated from Veradermics, Inc's SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$71.6M
FCF marginn/a
Share count change+1.1%

Financials

Fiscal years, $M
Item20242025
Revenuen/an/a
Operating income−27−72
Net income−26−70
Free cash flow−24−72

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations